EGFR+ NSCLC
Advertisement
FLAURA2 Principal Investigator, Pasi A. Jänne, MD, PhD, discusses the final overall survival analysis from the phase 3 ...
Osimertinib plus chemotherapy showed a “statistically significant and clinically meaningful improvement" in overall ...
In the second segment of this interview, Feldman discussed the importance of patient advocacy in clinical trial research.
Dr. Liu discusses the implications of the accelerated approval and what the future may hold.
Feldman presented on phase 2 patient-reported quality-of-life outcomes from the COCOON trial at the 2025 ASCO Annual Meeting.
The results of the interim analysis comparing safety and efficacy were presented at the 2025 ASCO Annual Meeting.
Researchers compared sacituzumab tirumotecan, a TROP2-directed antibody drug conjugate, with platinum-based chemotherapy.
The approval is for adults who have experienced disease progression on or after platinum-based chemotherapy.
The study investigated HER3-DXd in patients with advanced EGFRm NSCLC after progression during treatment with an EGFR TKI.
The approval is for adults who have received prior EGFR-directed therapy and platinum-based chemotherapy.
Dr. Califano discusses what the study showed about baseline mechanisms of resistance to osimertinib and associated outcomes.
Local therapy is recommended by NCCN guidelines, but how it is used in oligoprogressive disease is not well described.
Helena Yu, MD, discusses research updates from REZILIENT1 that were presented at ASCO 2025.
The study compared treatment with neoadjuvant osimertinib with or without chemotherapy versus chemotherapy alone.
Jennifer Carlisle, MD, discusses amivantamab, and the multidimensional impact of toxicity management at ASCO 2025.
Dr. Spira shares key data from cohort C of CHRYSALIS-2 that was presented at the European Lung Cancer Congress 2025.
Dr. Liu discusses key data and updates in EGFR-positive NSCLC from the European Lung Cancer Congress.
Nicolas Girard, MD, PhD, discusses data on subcutaneous amivantamab in patients with advanced NSCLC.
Suresh S. Ramalingam, MD, FACP, FASCO, presented the data during a proffered paper session at ELCC 2025.
The study is evaluating regimens to prevent dermatologic adverse events in patients receiving amivantamab plus lazertinib.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.